Working towards a cure in CML

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, reflects on the potential for a cure in patients with chronic myeloid leukemia (CML), highlighting treatment discontinuation in 20-25% of patients treated with a tyrosine kinase inhibitor (TKI). Future endeavors are focusing on increasing the percentage of patients with CML achieving prolonged remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

• Categoria